US Lawmakers Call for Sanctions Against China's WuXi Biotech
TL;DR
Lawmakers' explosive charges have put a global spotlight on China's WuXi, a major player in the biopharma industry, which is now facing increased scrutiny. The relationship between biopharma companies and global CRO/CDMOs can be disrupted by various issues such as regulatory issues, production snags, and questions about team leadership, impacting long-term projects with substantial stakes.
- Lawmakers' explosive charges turn a global spotlight on China's WuXi, and it's feeling the heat Endpoints News
- WuXi AppTec, WuXi Bio Slump as US Lawmakers Seek Formal Probe Bloomberg
- Chinese biotech firm Wuxi should be sanctioned, US lawmakers urge South China Morning Post
- Lawmakers urge White House officials to enforce sanctions on China's WuXi AppTec, WuXi Biologics: Reuters FiercePharma
- U.S. Lawmakers Seek Investigation Against China's WuXi AppTec The Wall Street Journal
Want the full story? Read the original reporting
Read on Endpoints News